IMB-808

• Description:

  IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1) . IMB-808 can be used as a promising agent for the prospective treatment of atherosclerosis research[1].

• UNSPSC:

  12352005

• Target:

  LXR

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/imb-808.html

• Concentration:

  10mM

• Purity:

  99.85

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(N(CC(NC1=CC=C(C(F)=C1F)F)=O)C)C2=CC=C3OCCOC3=C2

• Molecular Formula:

  C18H15F3N2O4

• Molecular Weight:

  380.32

• References & Citations:

  [1]Duo Lu, et al. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Mol Pharmacol. 2017 Apr;91 (4) :264-276.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  870768-70-0